Health plans are facing increasing pressure to manage the skyrocketing costs of specialty medications. Specialty drugs, while representing a small fraction of total prescriptions, now account for a substantial share of overall drug spending. As health plans work to balance financial sustainability with member access to high-cost therapies, one growing trend is the increased use of medical-benefit rebates over traditional pharmacy rebates. 

In the realm of healthcare delivery, a consistent and reliable supply of medications is a critical infrastructure. However, the current healthcare environment is marked by a disturbing trend: the persistent shortage of nearly 130 critical pharmaceuticals.

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.